drugset / Trial / NCT05525286
Clinical Trial of SOT102 Antibody Drug Conjugate in Patients With Advanced Gastric and Pancreatic Adenocarcinoma
Non-randomizedSequentialOpen-labelTreatment
Summary
This trial will assess the MTD and RP2D of SOT102 administered as monotherapy (Part A) and in combination with first-line SoC treatment (nab-paclitaxel/ gemcitabine; Part B) and efficacy of SOT102 administered as monotherapy (Part C) and in combination with first-line SoC treatment (Part D) in patients with advanced or metastatic pancreatic adenocarcinoma.
Timeline
- Start
- 2022-03-31
- Primary completion
- 2024-12-13
- Completion
- 2024-12-13
Outcome
Outcome not reported
Stopped: “Trial terminated by Sponsor based on benefit- risk reassessment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SOT102 | Other / unclassified | 0.032 mg/kg | Intravenous |
| Subject | SOT102 | Other / unclassified | 0.064 mg/kg | Intravenous |
| Subject | SOT102 | Other / unclassified | 0.128 mg/kg | Intravenous |
| Subject | SOT102 | Other / unclassified | 0.214 mg/kg | Intravenous |